ESR1 gene mutations and liquid biopsy in ER-positive breast cancers: A small step forward, a giant leap for personalization of endocrine therapy? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Cancers Année : 2023

ESR1 gene mutations and liquid biopsy in ER-positive breast cancers: A small step forward, a giant leap for personalization of endocrine therapy?

Résumé

The predominant forms of breast cancer (BC) are hormone receptor-positive (HR+) tumors characterized by the expression of estrogen receptors (ERs) and/or progesterone receptors (PRs). Patients with HR+ tumors can benefit from endocrine therapy (ET). Three types of ET are approved for the treatment of HR+ BCs and include selective ER modulators, aromatase inhibitors, and selective ER downregulators. ET is the mainstay of adjuvant treatment in the early setting and the backbone of the first-line treatment in an advanced setting; however, the emergence of acquired resistance can lead to cancer recurrence or progression. The mechanisms of ET resistance are often related to the occurrence of mutations in the ESR1 gene, which encodes the ER-alpha protein. As ESR1 mutations are hardly detectable at diagnosis but are present in 30% to 40% of advanced BC (ABC) after treatment, the timeline of testing is crucial. To manage this resistance, ESR1 testing has recently been recommended; in ER+ HER2− ABC and circulating cell-free DNA, so-called liquid biopsy appears to be the most convenient way to detect the emergence of ESR1 mutations. Technically, several options exist, including Next Generation Sequencing and ultra-sensitive PCR-based techniques. In this context, personalization of ET through the surveillance of ESR1 mutations in the plasma of HR+ BC patients throughout the disease course represents an innovative way to improve the standard of care.
Fichier principal
Vignette du fichier
cancers-15-05169.pdf (3.54 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04295094 , version 1 (20-11-2023)

Identifiants

Citer

Margaux Betz, Vincent Massard, Pauline Gilson, Andréa Witz, Julie Dardare, et al.. ESR1 gene mutations and liquid biopsy in ER-positive breast cancers: A small step forward, a giant leap for personalization of endocrine therapy?. Cancers, 2023, 15 (21), pp.5169. ⟨10.3390/cancers15215169⟩. ⟨hal-04295094⟩
19 Consultations
10 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More